Companies featured in this edition of the newsletter: ACTC, CVM, CHIP, ENZ, HYTM, IWEB, ONEZ, PHC, SIHI, SRCO

Markets continued their strong performance this week in the absence of any major market driving earnings or economic reports, as the broad based buying that characterized the previous week continued and led to gains in all of the major indices. All told, the Dow added 2.5% on the week, gaining 247 points to close at 10,270, up 17.0% on the year. The Nasdaq posted a 2.6% gain on the week, closing at 2,167 to extend its yearly gains to 37.5%, while the S&P 500 and Russell 2000 gained 2.3% and 1.0% respectively, bringing their yearly gains to 21.1% and 17.4%.

Equity markets carried the momentum from the previous week’s session, as the thin economic calendar and lack of significant earnings reports provided little incentive for investors to slow their buying activities.

...

Ardea Biosciences Inc. (RDEA) recently announced additional positive results from the completed first cohort of an ongoing mid-stage, proof-of-concept (POC) study of RDEA594, for the treatment of hyperuricemia (abnormally elevated uric acid levels) and gout. Data from the study were presented at a medical meeting in Philadelphia, Pennsylvania.  Results showed that RDEA594 significantly lowered serum uric acid levels in gout patients and was well tolerated with no serious adverse events and no premature discontinuations. Approximately 90% of the gout patient population consists of patients who excrete less than normal amounts of uric acid and are the primary target for treatment with RDEA594. At the same time, results also revealed that the drug is not more effective than current medication − allopurinol − a cheap generic.  Ardea is aiming to develop RDEA594 as an add-on or alternative for patients who do not benefit from the existing medications ...

Stress-related employee turnover, absenteeism and low morale all affect a company’s bottom line. Based on information from the American Institute of Stress and the American Psychological Association, job stress and related problems cost companies an estimated $200 billion or more a year.

Massage has been known to reduce blood pressure, relieve arthritis pain, improve joint and muscle aches, especially in painful areas of the neck and back, and even increase immunity to colds and flu. But what is not known is that massage services in the workplace can do wonders not only for a company’s morale but also for their profits.

Massage in general decreases job stress and fatigue while increasing alertness, clear thinking and productivity in employees. A recent study in the American Psychologist gave one group of workers a 15 minute rest while giving another group of workers a 15 minute

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Wednesday September 23, 2009

DrStockPick.com Stock Report!

**************************************************************

Plug Power Inc. (Nasdaq:PLUG), a leader in providing clean, reliable energy solutions, today announced that its GenDrive(tm) fuel cell solution has exceeded a combined total run time of one million operating hours at material handling customer sites across North America. Plug Power placed the first commercially available unit into the field in 2007 and currently is tracking 379 GenDrive units of its installed base.

PureSpectrum, Inc. (Pink Sheets: PSPM) will host an informational meeting to discuss the

...

Nutra Pharma has announced their intention to begin the registration for their over-the-counter pain reliever in both Canada and Europe. Currently, the company is marketing a similar product, Cobroxin, within the United States. Cobroxin is used for the treatment of moderate to severe (Stage 2) chronic pain.

According to the North American Chronic Pain Association of Canada, it is estimated that 18% of Canadians suffer from severe chronic pain. Additionally, the Pain in Europe report, which is the largest European survey of chronic pain sufferers, reports that chronic pain effects one in five adults across Europe.

Dr. Paul Redi, CEO of ReceptoPharm, stated, “We have already started in-depth conversations with regulatory specialists with the intent to begin the registration of our over-the-counter pain reliever in Canada and Europe. We are confident that our pain reliever can be successfully registered in the near term based on the existing regulatory requirements in those

...

Biomedical company Vivakor Inc. announced today the results of independent, third-party testing of its VivaBlend nutraceutical product. This product is a powerful extract developed by Vivakor scientists and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, the company’s scientists created an optimum blend of super-oxidants, flavonoids and powerful plant phenolics.

The results from third-party testing show that VivaBlend contains a much higher level of antioxidants, phytochemicals and lipophilic antioxidants, from a wider array of plant sources, than its competitors. Lipophilic antioxidants penetrate the lipoprotein cell membrane more easily than other antioxidants and are therefore retained in the body longer (bioactive).

Scientists are still discovering the benefits of these potent natural chemicals in improved health and wellness. Data has shown, however, that different types of antioxidants and phytochemicals collectively may reduce the adverse effects of aging and may lessen the risk of

...

Nutra Pharma Corp.

(Public, OTC:NPHC)

Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The

...

Today, Nutra Pharma Corp., a biotechnology company that develops treatments for AMN, HIV and Multiple Sclerosis, announced the launch of an over-the-counter pain reliever, Cobroxin, for the treatment of Stage 2 chronic pain. Cobroxin is the first clinically approved OTC pain reliever for Stage 2 pain.

The drug, developed by Nutra Pharma’s subsidiary, ReceptoPharm, will be available as an oral spray. It is designed to treat lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia. It will also be available as a topical gel for treating repetitive stress, arthritis, and joint pain.

Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation, commented, “Cobroxin is a next generation pain reliever that addresses physician and consumer demand for a safer and less costly treatment for chronic pain. Cobroxin provides affordable and accessible pain relief for those without healthcare coverage, for those looking for a safer and effective treatment for pain,

...

On Friday, Ardea Biosciences Inc. (RDEA) posted a second-quarter net loss of $8 million, or 44 cents per share, which was significantly lower than the Zacks Consensus Estimate of 60 cents per share. The company had reported a net loss of $15.7 million, or $1.10 per share in the year-ago period.

The narrower quarterly loss was attributable to the licensing payment from Bayer and lower expenses. Revenue of $5.5 million came from recognition of a part of the $35 million upfront payment under the Bayer agreement on development of MEK inhibitors for treatment of cancer and other indications. Ardea had registered no sales in the year-ago quarter.

Operating expenses for the quarter fell 19% to $13.2 million primarily on lower costs for discovery research since Ardea is concentrating its resources on development of its gout candidate, RDEA594, which is in mid-stage study. The decrease was partially offset by

...

On Friday, shareholders of Merck & Co. (MRK) and Schering-Plough Corp. (SGP) gave their nod of approval to the proposed merger of the two drugmakers. The deal, scheduled to close in the fourth quarter of this year, was approved by 99% of voters from each company.

The merger still has to be approved by regulators in the U.S. and other countries before it becomes operational. The $41.1 billion deal will be paid for with a combination of cash and stock.

As a reminder, the two companies entered into the merger agreement in March 2009. Schering-Plough shareholders will receive 0.5767 Merck shares and $10.50 for each stock they own. The companies expect the deal to produce $3.5 billion in annual cost savings as 15% of the combined workforce would be shown the door. The merger is likely to be slightly accretive to earnings in the first year and

...